Condition: Myeloproliferative Disease · Inflammatory Markers · Sponsor: University of Milano Bicocca
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
This description comes directly from the study's public registry record.
Elena Maria Elli · 0392339859 · elena.elli@libero.it
Benedetta Valeri · benedettavalerihsg@gmail.com
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliera Universitaria Consorziale Policlinico | Bari, Italy | Recruiting |
| Policlinico Sant'Orsola Malpighi | Bologna, Italy | Recruiting |
| ASST Spedali Civili di Brescia | Brescia, Italy | Recruiting |
| Policlinico Vittorio Emanuele | Catania, Italy | Recruiting |
| Ospedale Universitario Federico II | Naples, Italy | Recruiting |
| Policlinico Umberto I, Università La Sapienza | Roma, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Città della Salute e delle Scienza | Torino, Italy | Recruiting |
| Ospedale San Luigi di Orbassano - Ospedale Mauriziano | Torino, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Friuli Centrale | Udine, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Integrata | Verona, Italy | Recruiting |
| Ospedale Belcolle | Viterbo, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05553873